1132-P: Real-World Clinical Use of iGlarLixi in a Large U.S. Electronic Medical Records Database
Authors: FRIAS JUAN P. , BOSS ANDERS H. , LUBWAMA ROBERT , SHAUNIK ALKA 
Published: June 2019

iGlarLixi, a fixed-ratio combination of insulin glargine U100 (iGlar-100) and the GLP-1 RA lixisenatide, has been available in the U.S. for clinical use in patients (pts) with T2D since 01/2017. This analysis provides baseline characteristics of iGlarLixi pts and prescribers in a real-world setting from a U.S. electronic medical records database. Pts initiating iGlarLixi from 01/2017 were reviewed using the U.S. Optum Humedica database, which includes data from approximately 85 million pt lives (insured and uninsured). Pts with at least 6 months’ data prior to iGlarLixi initiation (07/2016) were included. Baseline characteristics and clinical variables using ICD-9-CM/ICD-10-CM and prescription codes were extracted. Among 1075 total pts initiating iGlarLixi, mean age was 56.5 years (SD 10.6, range 22-89); highest number of pts (41%) were 55-64 years; 53% were female. If noted, race was 76% Caucasian, 16% African American, 1% Asian, and 8% Other/Unknown; 6% were of Hispanic ethnicity. Mean HbA1c was 9.1% (SD 2.0, median 8.8); distribution: ≥7% (80%), ≥8% (60%), and ≥9% (41%). Mean BMI (kg/m2) was 36.1 (SD 6.9, median 35.4); BMI was ≥30 for 50% and 30-&lt;40 for 35%. Mean eGFR (mL/min/1.73 m2) was 86 (SD 26.8); of pts with known eGFR, 84% had &gt;60. Mean Diabetes Complications Severity Index (DCSI) score was 2.4 (SD 1.7); 35% had DCSI ≥3. Previous basal insulin (BI) therapy (± OADs) was used by 41%; 14% were on GLP-1 RAs (± OADs); 15% were on BI + GLP-1 RA free combination (± OADs); 15% were on at least one OAD, without BI or GLP-1 RA. OADs (≥1) were used by 72% of pts; 38% were on ≥2 OADs. The highest number of pts were from the Midwest (61%), followed by the South (27%). Over 60% of prescribers were mid-level/family practice/internal medicine; 15% were endocrinologists.

In conclusion, iGlarLixi is used for pts with a wide range of baseline demographic and clinical characteristics in widespread U.S. geographic regions. The largest use was noted in pts with high HbA1c and obesity, and most pts had previous therapies of BI or GLP-1 RAs and OADs.

Disclosure

J.P. Frias: Advisory Panel; Self; Becton, Dickinson and Company, Eli Lilly and Company, Gilead Sciences, Inc., Sanofi. Consultant; Self; Echosens, Genentech, Inc., Johnson & Johnson Diabetes Institute, Novo Nordisk Inc., Zafgen, Inc. Research Support; Self; AbbVie Inc., Akcea Therapeutics, Allergan, Amgen Inc., AstraZeneca, Bayer US, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Cirius Therapeutics, Elcelyx Therapeutics, Inc., Eli Lilly and Company, Enanta Pharmaceuticals, Inc., GENFIT, Intarcia Therapeutics, Inc., Intercept Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., NGM Biopharmaceuticals, Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, Oramed Pharmaceuticals, Pfizer Inc., Sanofi, TaiwanJ Pharmaceuticals Co., Ltd., Theracos, Inc. Speaker's Bureau; Self; Merck & Co., Inc., Sanofi. A.H. Boss: Employee; Self; Sanofi. Stock/Shareholder; Self; Novo Nordisk A/S, Sanofi. R. Lubwama: Employee; Self; Merck & Co., Inc., Sanofi. A. Shaunik: Employee; Self; Sanofi.

Funding

Sanofi